Search for: All records

Public blockchains have spurred the growing popularity of decentralized transactions and smart contracts, especially on the financial market. However, public blockchains exhibit their limitations on the transaction throughput, storage availability, and compute capacity. To avoid transaction gridlock, public blockchains impose large fees and per-block resource limits, making it difficult to accommodate the ever-growing high transaction demand. Previous research endeavors to improve the scalability and performance of blockchain through various technologies, such as side-chaining, sharding, secured off-chain computation, communication network optimizations, and efficient consensus protocols. However, these approaches have not attained a widespread adoption due to their inability in delivering a cloud-like performance, in terms of the scalability in transaction throughput, storage, and compute capacity. In this work, we determine that the major obstacle to public blockchain scalability is their underlying unstructured P2P networks. We further show that a centralized network can support the deployment of decentralized smart contracts. We propose a novel approach for achieving scalable decentralization: instead of trying to make blockchain scalable, we deliver decentralization to already scalable cloud by using an Ethereum smart contract. We introduce Blockumulus, a framework that can deploy decentralized cloud smart contract environments using a novel technique called overlay consensus. Through experiments, we demonstrate that Blockumulus is scalable in all three dimensions: computation, data storage, and transaction throughput. Besides eliminating the current code execution and storage restrictions, Blockumulus delivers a transaction latency between 2 and 5 seconds under normal load. Moreover, the stress test of our prototype reveals the ability to execute 20,000 simultaneous transactions under 26 seconds, which is on par with the average throughput of worldwide credit card transactions. 

Abstract In less than nine months, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) killed over a million people, including >25,000 in New York City (NYC) alone. The COVID-19 pandemic caused by SARS-CoV-2 highlights clinical needs to detect infection, track strain evolution, and identify biomarkers of disease course. To address these challenges, we designed a fast (30-minute) colorimetric test (LAMP) for SARS-CoV-2 infection from naso/oropharyngeal swabs and a large-scale shotgun metatranscriptomics platform (total-RNA-seq) for host, viral, and microbial profiling. We applied these methods to clinical specimens gathered from 669 patients in New York City during the first two months of the outbreak, yielding a broad molecular portrait of the emerging COVID-19 disease. We find significant enrichment of a NYC-distinctive clade of the virus (20C), as well as host responses in interferon, ACE, hematological, and olfaction pathways. In addition, we use 50,821 patient records to find that renin–angiotensin–aldosterone system inhibitors have a protective effect for severe COVID-19 outcomes, unlike similar drugs. Finally, spatial transcriptomic data from COVID-19 patient autopsy tissues reveal distinct ACE2 expression loci, with macrophage and neutrophil infiltration in the lungs. These findings can inform public health and may help develop and drive SARS-CoV-2 diagnostic, prevention, and treatment strategies.